SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic ...

With its robust fibrosis benefit shown in clinical trials to date, potential best-in-class tolerability and safety profile, and convenient dosing, pegozafermin has the potential to significantly ...

(ETNB), highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of enrollment in our Phase 3 ENTRUST trial in SHTG,” stated Rohan Palekar, ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe ...

So the 3-reader approach that we're using is identical to the approach used by 89Bio on pegozafermin in their trial. We think they learned a tremendous amount by their predecessors. And this 3 ...

The results of a phase 2b ENLIVEN trial of FGF21 analogue pegozafermin showed it was able to reduce scarring (fibrosis) in the liver of NASH patients at more than three times the rate of a placebo ...

2024 at 8:20 AM ET and participate in one-on-one investor me New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which ...